Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.

Article  PubMed  PubMed Central  Google Scholar 

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–82.

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Sisó-Almirall A. Immune-related adverse events of immune checkpoint inhibitors. Ann Intern Med. 2024;177(2):itc17–itc32.

Haryal A, Townsend MJ, Baskaran V, Srivoleti P, Giobbie-Hurder A, Sack JS, et al. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023;129(3):367–75.

Article  CAS  PubMed  Google Scholar 

Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, et al. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54(5):538–45.

Article  CAS  PubMed  Google Scholar 

Bresteau C, Bonnet P, Robert C, Mussini C, Saiag P, Buecher B, et al. Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series. J Gastroenterol Hepatol. 2023;38(12):2104–10.

Article  CAS  PubMed  Google Scholar 

Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2020;76(2):233–43.

Article  PubMed  Google Scholar 

Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28(11):2860–5.

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.

Article  PubMed  PubMed Central  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–126.

Article  CAS  PubMed  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(4):387–405.

Article  CAS  PubMed  Google Scholar 

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264–iv6.

Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160(4):1384–93.

Article  CAS  PubMed  Google Scholar 

Singh BP, Marshall JL, He AR. Workup and management of immune-mediated colitis in patients treated with immune checkpoint inhibitors. Oncologist. 2020;25(3):197–202.

Article  PubMed  Google Scholar 

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ecker ME, Weckauf H, Tebbe S, Schuppert F. Immune-mediated gastritis in a patient with metastatic lung cancer due to therapy with the immune checkpoint inhibitor Pembrolizumab—differences and similarities in comparison to “endogenous” autoimmune type A gastritis and a review of literature. Z Gastroenterol. 2023;61(10):1385–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar SS, Arvind S, Umpierrez AP. Things we do for no reason™: routine use of proton pump inhibitors for peptic ulcer prophylaxis in adults on high-dose corticosteroids. J Hosp Med. 2023;18(7):630–2.

Article  PubMed  Google Scholar 

Shatila M, Lu L, Glombicki S, Baerman E, Aleem A, Catinis C, et al. 719 the impact of proton-pump inhibitor use on the incidence of gastrointestinal toxicity to checkpoint inhibition. Gastroenterology. 2024;166:S-172.

Article  Google Scholar 

Mohan A, Krisanapan P, Tangpanithandee S, Thongprayoon C, Kanduri SR, Cheungpasitporn W, et al. Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes. Am J Nephrol. 2024;55(4):439–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elmasry M, Dong B, Rios C, Breaux A, Miller D. Delayed hemorrhagic gastritis caused by immunotherapy in a patient with metastatic melanoma. Am J Med Sci. 2022;364(3):343–6.

Article  PubMed  Google Scholar 

Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica. 2019;111(3):92–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hayama N, Ihara H, Honma Y, Itoigawa Y, Kaira K, Fujii M. Severe gastritis due to pembrolizumab treatment in a lung cancer patient. Respirol Case Rep. 2020;8(7):e00636.

Article  PubMed  PubMed Central  Google Scholar 

Satila M, Cruz CC, Rivera A, Sullivan A, Abdul-Baki K, Lee IJ, et al. S1435 mystery diarrhea: a comparative analysis of immune-mediated colitis disease characteristics among patients with and without signs of inflammation on initial work-up. Am J Gastroenterol. 2024;119(10S):S1030-1.

Article  Google Scholar 

Ahmed A, Clarke JO. Proton pump inhibitors (PPI). StatPearls. Treasure Island: StatPearls Publishing LLC; 2024.

Numico G, Fusco V, Franco P, Roila F. Proton pump inhibitors in cancer patients: how useful they are? A review of the most common indications for their use. Crit Rev Oncol Hematol. 2017;111:144–51.

Article  PubMed  Google Scholar 

Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or Ranitidine versus Placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18:463–7.

Woodford R, Briscoe K, Tustin R, Jain A. Immunotherapy-related gastritis: two case reports and literature review. Clin Med Insights Oncol. 2021;15:11795549211028570.

Article  PubMed  PubMed Central  Google Scholar 

Yu LL, He ZL, Qian XL. Managing immune checkpoint inhibitor-associated gastritis: insights and strategies. World J Gastroenterol. 2024;30(24):3120–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9.

Article  PubMed  PubMed Central  Google Scholar 

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38.

Article  CAS  PubMed  Google Scholar 

Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: a case report. World J Gastroenterol. 2020;26(16):1971–8.

Article  PubMed  PubMed Central  Google Scholar 

Tran CN, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab achieved clinical and histologic remission in a patient with lung cancer who had a steroid-refractory upper gastrointestinal injury due to nivolumab treatment. J Immunother Precis Oncol. 2019;2:40–5.

Article